Aarti Pharmalabs Ltd

Aarti Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Pharmalabs Ltd

₹ 653 5.91%
22 Nov - close price
aartipharmalabs.com BSE: 543748 NSE: AARTIPHARM
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Aarti Pharmalabs Limited (APL) formerly known as Aarti Organics was established in 1984 as a WOS of Aarti Industries Limited. Got demerged in Oct,22 into a separately listed entity.
Co. is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives and offers CDMO/CMO services. Company has 6 manufacturing plants and 3 R&D centres.

Website BSE NSE
  • Market Cap ₹ 5,922 Cr.
  • Current Price ₹ 653
  • High / Low ₹ 722 / 381
  • Stock P/E 28.7
  • Book Value ₹ 188
  • Dividend Yield 0.46 %
  • ROCE 16.4 %
  • ROE 13.1 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Promoter holding has decreased over last quarter: -0.36%
  • Company has a low return on equity of 13.6% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Allcap BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
365 373 404 359 374 358 356 373 415 393 377
296 294 324 287 297 281 282 285 307 310 293
Operating Profit 68 79 80 73 77 77 74 88 107 84 85
OPM % 19% 21% 20% 20% 21% 21% 21% 24% 26% 21% 22%
3 0 1 0 0 5 0 0 6 2 3
Interest 4 4 6 5 6 4 4 4 4 4 5
Depreciation 12 12 15 15 14 15 16 17 17 18 19
Profit before tax 54 62 61 53 57 62 54 67 91 63 63
Tax % 17% 24% 25% 27% 30% 23% 22% 29% 31% 25% 25%
45 47 46 39 40 48 42 48 63 47 48
EPS in Rs 4.25 4.41 5.26 4.61 5.32 6.95 5.20 5.28
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
0 941 1,511 1,502 1,559
0 761 1,203 1,156 1,195
Operating Profit 0 180 308 346 364
OPM % 19% 20% 23% 23%
0 3 1 11 11
Interest 0 11 20 17 18
Depreciation 0 37 56 66 71
Profit before tax 0 134 233 275 285
Tax % 20% 26% 27%
0 107 172 201 206
EPS in Rs 18.95 22.14 22.75
Dividend Payout % 0% 11% 14%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 23%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 65%
Return on Equity
10 Years: %
5 Years: %
3 Years: 14%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 0.25 0.25 45 45 45
Reserves -0 1,284 1,393 1,576 1,662
0 327 208 272 386
0 215 330 404 412
Total Liabilities 0 1,827 1,976 2,297 2,506
0 701 848 953 1,125
CWIP 0 187 102 137 116
Investments 0 40 55 62 60
0 898 971 1,145 1,205
Total Assets 0 1,827 1,976 2,297 2,506

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 -65 216 184
0 -134 -116 -184
0 255 -157 4
Net Cash Flow 0 56 -56 4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 118 90 109
Inventory Days 359 240 283
Days Payable 106 95 124
Cash Conversion Cycle 371 235 268
Working Capital Days 263 168 197
ROCE % 18% 16% 16%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
45.98% 45.98% 46.30% 46.46% 46.46% 46.46% 46.10%
7.69% 7.43% 8.45% 8.17% 8.33% 7.07% 7.38%
13.68% 10.65% 10.51% 9.91% 9.97% 11.47% 11.35%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
32.64% 35.92% 34.73% 35.45% 35.24% 35.00% 35.17%
No. of Shareholders 2,76,6642,58,2392,26,2862,15,7962,04,1221,89,0121,85,436

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls